The effect in the lungs could be partially blocked by an anti-IL-17 blocking antibody administered post-challenge, supporting the already-published theory of a role for IL-17 in vaccine-mediated protection against TB disease [3], [4], [30]. The gene discussed is IL17A; the disease is tuberculosis.